Alaunos Therapeutics, Inc. (TCRT)
| Market Cap | 104.56M |
| Revenue (ttm) | 398,000 |
| Net Income (ttm) | -66.99M |
| Shares Out | 215.95M |
| EPS (ttm) | -0.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,518,254 |
| Open | 0.505 |
| Previous Close | 0.520 |
| Day's Range | 0.480 - 0.520 |
| 52-Week Range | 0.410 - 3.730 |
| Beta | 1.55 |
| Analysts | Buy |
| Price Target | 3.88 (+701.3%) |
| Earnings Date | May 16, 2022 |
About TCRT
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc....
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for TCRT stock is "Buy." The 12-month stock price forecast is 3.88, which is an increase of 701.32% from the latest price.
News
Alaunos Therapeutics Reports First Quarter 2022 Financial Results
Successfully dosed first patient in TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications
Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference
HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S. Boy...
Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022
HOUSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the first quarter ended March ...
Penny Stocks With Huge Potential According To 4 Wall Street Analysts
Penny stocks with huge potential according to analysts in 2022. The post Penny Stocks With Huge Potential According To 4 Wall Street Analysts appeared first on Penny Stocks to Buy, Picks, News and Infor...
What Makes Ziopharm (TCRT) a New Buy Stock
Ziopharm (TCRT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting
HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a poster presenta...
Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tu...
HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that the first pa...
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
HOUSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced financial resul...
Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022
HOUSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the fourth quarter ended Dec...
Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference
HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that the Compa...
Ziopharm Rebrands As Alaunos Therapeutics
The Company will trade on NASDAQ under the new ticker symbol "TCRT" to be effective tomorrow.
Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics
HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), a clinical-stage oncology-focused cell therapy company, today highlighted recent operatio...
Why Ziopharm Oncology Shares Rose 10.5% on Wednesday
The clinical-stage biotech saw a slight bounce-back from its lows of last week.
ZIOPHARM Oncology (ZIOP) Sees Hammer Chart Pattern: Time to Buy?
ZIOPHARM Oncology (ZIOP) has been struggling lately, but the selling pressure may be coming to an end soon.
Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Can...
HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the presentation of preclinical data highlighting the potential of neoant...
Ziopharm Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update
HOUSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced financial results for the third quarter ended September 30, 2021 and prov...
Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021
HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it will report financial results for the third quarter ended Septemb...
Best Penny Stocks To Buy Right Now? 3 Short Squeeze Stocks To Watch
Are short squeeze penny stocks part of your Q4 strategy? The post Best Penny Stocks To Buy Right Now?
Ziopharm (ZIOP) Down on Workforce Reduction Announcement
Ziopharm's (ZIOP) stock price falls after the announcement of several restructuring changes to advance the TCR program.
Ziopharm Shares Are Trading Lower After Slashing Workforce By Over 50%
Ziopharm Oncology Inc (NASDAQ: ZIOP) announced a restructuring enabling the Company to advance its TCR program. The Company will eliminate approximately 60 positions and expects the changes will extend...
Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway
• Over 50% reduction in personnel
Here's Why Ziopharm Oncology Stock Is Up 18% This Week
Recent insider stock purchases were more than a little encouraging.
Is the Options Market Predicting a Spike ZIOPHARM (ZIOP) Stock?
Investors need to pay close attention to ZIOPHARM (ZIOP) stock based on the movements in the options market lately.
Why Shares of Ziopharm Oncology Jumped on Wednesday
The company hopes to develop cancer treatments based on individualized gene therapies, and has two promising pipeline candidates.